Gisev家庭办公室

2020年10月23日

Solarea生物宣布系列S2G企业领导的融资和大胆Capital Partners Solarea生物,位于剑桥的生物技术公司,开发microbial-based解决方案来帮助人类健康,今天宣布它已经筹集了11.2美元的一系列S2G企业领导的融资和大胆Capital Partners,以及海盗的持续投资全球和额外投资Gisev家庭办公室作为一个集团的投资者。Solarea迅速建立了一个平台来确认地址新型产品广泛的慢性健康疾病。公司产生了一个庞大而独特的数据库的完整基因组序列的微生物来源于健康的食物。使用计算方法,Solarea产生协同组合的细菌,真菌和生命起源以前的纤维具有强大的抗炎功能来解决特定慢性病困扰很多人。这些已经在临床验证体外和体内小鼠模型。Solarea的第一个应用程序旨在帮助代谢过程的膳食管理,导致骨量减少和绝经后妇女的骨质疏松症。这提供了一种自然的解决方案来改善妇女的健康和幸福。肌肉骨骼疾病,包括骨质疏松症,骨量减少,骨关节炎,是全球残疾的主要原因。在美国,approximately 10 million Americans are currently living with osteoporosis or osteopenia, and one in three women over age 50 will experience an osteoporosis related fracture. Tragically, hip fractures have a one-year mortality rate of 30% and a two-year of close to 56%. Solarea believes a natural, microbial-based solution will have a positive impact on the quality of life of millions of women worldwide who are at risk for these musculoskeletal disorders and aid in improving health outcomes. Solarea will use the proceeds from its Series A fundraise to advance its musculoskeletal product, SBD111, through a clinical proof of activity trial as well as continue the discovery and development of its ongoing pipeline of microbial-based products. “We are very excited for Solarea to enter this stage with such a great team of investors. Our team is completely aligned in our view of the future of food as medicine and the process to develop and commercialize novel microbial-based solutions. We see a clear link between analyzing healthy foods and creating new products to improve the lives of patients in need,” says Gerardo V Toledo, Solarea’s CEO and Co-founder. Matthew Walker, Managing Director at S2G Ventures notes: “Solarea is developing products that combat diseases of inflammation through the gut microbiome in a way that works synergistically with the body and is backed by rigorous preclinical sudies. As we continue to see a convergence between food and medicine, we’re delighted to partner with Bold Capital, Viking Global, and the Gisev Family Office to help support this exceptional team in their mission to use food-based tools to improve human health.” Neal Bhadkamkar, General Partner at Bold comments: “Solarea is a quintessential Bold portfolio company – a passionate and deeply knowledgeable team seeking to create meaningful societal impact by harnessing the power of exponential technologies, in this case sequencing and computational biology. We are eager to see Solarea’s first products get to market and improve the bone health of millions of women and men worldwide. Bold Capital, Viking and other early investors stepped in to support Solarea as it left the Illumina Accelerator two years ago. We are thrilled to see the company take this next step in its journey with S2G Ventures and Gisev Family Office joining the investor group.” Sign Up to Free Newsletter The Microbiome Drug Database